StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $7.29 | $6.75 | -7.41% | 0.0M |
| 05-12 | $6.70 | $6.50 | -2.99% | 0.0M |
| 05-13 | $6.55 | $6.31 | -3.66% | 0.0M |
| 05-14 | $6.39 | $6.45 | +0.94% | 0.0M |
| 05-15 | $6.39 | $6.53 | +2.19% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $22.00K | $71.00K | $19.00K | $14.00K |
Operating Income | $-8.04M | $-21.81M | $-15.00M | $-10.16M |
Net Income | $-60.00K | $401.00K | $1.66M | $7.05M |
EPS (Diluted) | $-4.42 | $-5.63 | $-0.11 | $0.13 |
Total Assets | $45.42M | $38.81M | $38.07M | $43.89M |
Total Liabilities | $20.43M | $16.51M | $12.28M | $12.47M |
Cash & Equivalents | $6.46M | $1.54M | $3.10M | $4.00M |
Free Cash Flow OCF − CapEx | $-2.64M | $-5.24M | $-3.67M | $-2.77M |
Shares Outstanding | 6.27M | 927.93K | 23.05M | 20.14M |
No sell-side coverage available for PAVM.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for PAVM.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.